Endometrial cancer (EC) is a common gynecological malignancy. Over the past 20 years, molecular profiling of EC has played a crucial role in guiding individualized patient care and improving prognostic evaluation [1]. Previous studies have generally classified EC into four molecular subtypes: (1) DNA polymerase epsilon (POLE)-mutated, with pathogenic mutations in the exonuclease domain of POLE; (2) mismatch repair-deficient (dMMR), with loss of mismatch repair proteins; (3) p53-mutant, with a lo…